NLRP3-IN-21

• UNSPSC Description:

  NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 inflammasome activation and pyroptosis by suppressing gasdermin D cleavage, ASC oligomerization, and NLRP3 inflammasome assembly[1].

• Target Antigen:

  NOD-like Receptor (NLR)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/nlrp3-in-21.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1N(N=C(N2C1=CC3=C2C=C(S3)Cl)C(C)C)CC4=NN=C(O4)C5=CC=C(N=C5Cl)C(F)(F)F

• Molecular Weight:

  529.32

• References & Citations:

  [1]Na Li, et al. Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis. J Med Chem. 2023 Oct 12;66(19):13428-13451.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2956791-61-8